|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,046.00 DKK | +0.69% |
|
+0.15% | +37.09% |
| 01:33pm | Genmab announces data from multiple clinical trials | RE |
| 01:33pm | Genmab presents phase 3 data from EPCORE FL-1 trial | RE |
Business description: Genmab A/S
- royalties (80.6%);
- income from research and development (9.3%);
- other (10.1%): primarily income from partnership agreement.
At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).
Number of employees: 2,681
Sales by Activity: Genmab A/S
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Biotechnology | 1.01TCr | 848.2Cr | 1.46TCr | 1.65TCr | 2.15TCr |
Geographical breakdown of sales: Genmab A/S
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Denmark | 1.01TCr | 848.2Cr | 1.46TCr | 1.61TCr | 1.98TCr |
United States of America | - | - | - | 38Cr | 90Cr |
Japan | - | - | - | 4.1Cr | 84Cr |
Executive Committee: Genmab A/S
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 47 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
Tahamtan Ahmadi
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/02/2021 |
Andrew Carlsen
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: Genmab A/S
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 74 | 01/01/2015 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 65 | 01/01/2017 |
Deirdre Connelly
CHM | Chairman | 64 | 26/03/2020 |
| Director/Board Member | 52 | 29/03/2019 | |
| Director/Board Member | 60 | 29/03/2022 | |
Martin Schultz
BRD | Director/Board Member | 50 | 01/01/2022 |
Holdings: Genmab A/S
| Name | Equities | % | Valuation |
|---|---|---|---|
GENMAB A/S 4.13% | 26,51,727 | 4.13% | 84,01,63,371 $ |
Company details: Genmab A/S
Bio Therapeutic Drugs
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.69% | +0.15% | +31.03% | -36.79% | 1.95TCr | |
| +1.82% | +1.66% | +34.14% | +109.61% | 5.49TCr | |
| -0.51% | -1.81% | +170.56% | +977.65% | 4.35TCr | |
| +0.90% | -0.87% | +63.71% | +14.60% | 3.81TCr | |
| +0.26% | -6.69% | -20.93% | -40.82% | 2.31TCr | |
| +0.98% | +3.85% | +73.37% | -40.70% | 1.73TCr | |
| +0.24% | +3.15% | +87.49% | +220.62% | 1.47TCr | |
| -2.66% | +2.35% | -1.24% | +494.48% | 1.41TCr | |
| -3.09% | +1.32% | +134.63% | - | 1.38TCr | |
| -1.52% | -3.30% | +79.93% | +757.04% | 1.31TCr | |
| Average | -0.29% | -0.68% | +65.27% | +272.86% | 2.52TCr | |
| Weighted average by Cap. | +0.21% | -1.20% | +68.54% | +280.67% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GMAB Stock
- Company Genmab A/S
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition